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Purpose: Although heart failure (HF) is recognized as a leading contributor to healthcare costs and a significant economic bur-
den worldwide, studies of HF-related costs in South Korea are limited. This study aimed to estimate HF-related costs per Korean 
patient per year and per visit.
Materials and Methods: This retrospective cohort study analyzed data obtained from six hospitals in South Korea. Patients with 
HF who experienced ≥one hospitalization or ≥two outpatient visits between January 1, 2013 and December 31, 2013 were includ-
ed. Patients were followed up for 1 year [in Korean won (KRW)].
Results: Among a total of 500 patients (mean age, 66.1 years; male sex, 54.4%), the mean 1-year HF-related cost per patient was 
KRW 2,607,173, which included both, outpatient care (KRW 952,863) and inpatient care (KRW 1,654,309). During the post-index 
period, 22.2% of patients had at least one hospitalization, and their 1-year costs per patient (KRW 8,530,290) were higher than 
those of patients who had only visited a hospital over a 12-month period (77.8%; KRW 917,029). Among 111 hospitalized patients, 
the 1-year costs were 1.7-fold greater in patients (n=52) who were admitted to the hospital via the emergency department (ED) 
than in those (n=59) who were not (KRW 11,040,453 vs. KRW 6,317,942; p<0.001).  
Conclusion: The majority of healthcare costs for HF patients in South Korea was related to hospitalization, especially admissions via 
the ED. Appropriate treatment strategies including modification of risk factors to prevent or decrease hospitalization are needed to 
reduce the economic burden on HF patients.
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INTRODUCTION
The prevalence of heart failure (HF) increases with age. Lee, et 
al.1 estimated the overall prevalence of HF in South Korea at 
1.5% and increases from about 1.0% in adults aged 40–59 years 
to 5.5% in persons aged 60–60 years and to 12.6% among those 
aged ≥80 years. The number of patients primarily diagnosed 
with HF-specific International Classification of Disease, 10th 
edition (ICD-10) codes (I50, I50.1, and I50.9) increased from 
109224 in 2011 to 121159 in 2015 in South Korea.2 As the total 
number of people with HF has increased around the world 
with rapid aging populations, HF has been identified as a major 
public health and economic issue. In a number of studies inves-
tigating the economic burden of HF on the healthcare system, 
a 1–2% healthcare expenditure burden was attributed to HF in 
Europe and North America.3,4 According to the statistics pro-
vided by the Health Insurance Review and Assessment Ser-
vice (HIRA), HF-related spending in the reimbursed service in-
creased by 44.6% (62–89 billion won), and the annual cost per 
person grew by 30% from 2011 to 2015 for primary diagnosis of 
I50.x codes.2 This cost is likely underestimated, because it was 
based on claims data derived from reimbursement and exclud-
ed secondary diagnoses and other ICD-10 codes of HF. 
The European Society of Cardiology guideline defines chronic 
HF (CHF) as a syndrome in which patients have had stable HF 
that remains unchanged for more than 1 month, while it defines 
acute HF (AHF) as a rapid onset of new HF or acute decompen-
sation of pre-existing CHF.5 Hospital admission is generally need-
ed to treat AHF, which is often recurrent, since it is not a single 
organ disease itself but a complex clinical syndrome with a pro-
gressive and cyclical decline. The main social and economic 
burden of HF is associated with hospital admission, and hos-
pitalization accounts for up to 70% of total HF costs. A study 
published in 2012 showed that hospital costs related to admis-
sion accounted for roughly 85% of all costs.6-8 Considering this 
evidence, many studies have aimed to identify risk factors of hos-
pitalization and re-hospitalization, and most studies of health-
care cost have focused only on hospitalized HF patients and 
did not consider stable CHF patients. In South Korea, there are 
limited data regarding healthcare costs and utilization for pa-
tients with HF. 
Therefore, the objective of this study was to estimate HF-re-
lated costs and resource utilization of patients with AHF or sta-
ble CHF and to identify risk factors contributing to HF-related 
costs per patient per year in Korea. 
MATERIALS AND METHODS
Study population 
We conducted this retrospective observational cohort study at 
five tertiary hospitals and one general hospital in South Korea. 
Patients from tertiary referral hospitals comprised 88% of the 
entire study population. Patients enrolled in the study were 18 
years or older and diagnosed with a HF-specific ICD-10 code 
(I50.0, I50.1, I50.9, I11.0, I13.0, I13.2) between January 1, 2013 
and December 31, 2013 (Fig. 1). An index date corresponding 
to the date of the first HF-related visit was assigned to each 
sample, and all subjects were followed for up to 1 year from the 
index date. Subjects were included if they had ≥one HF-relat-
ed hospitalization or ≥two HF-related outpatient visits. Patients 
were excluded if they underwent chemotherapy or participat-
ed in an intervention clinical trial in the post-index period.
   
Stratification 
A well-chosen sample can be representative of the entire pop-
ulation. Several studies have found that hospitalization care is 
associated with greater cost and resource use in patients with 
HF. Patients were divided by hospitalization history during the 
post-index period and identified by stratified proportionate 
sampling, because the proportion of hospitalized patients leads 
to higher costs and resource utilization. Fifteen to 30 percent 
of the patients would likely be hospitalized according to claims 
database analyses using the HIRA National Patient Sample, 
2012/01/01
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Fig. 1. Study design. BMI, body mass index; LVEF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate; NYHA, New York Heart 
Association; HF, heart failure. 
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within which we identified the study population. 
Outcome measures
The endpoints of this study were HF-related healthcare costs 
and resource utilization during the 12-month analysis period fol-
lowing the index date. Outpatient visit, emergency department 
(ED) visit, hospitalization, and medications were assessed us-
ing both medical and prescription data. HF medication classes 
include angiotensin-converting enzyme inhibitors (ACEI), an-
giotensin II receptor blockers (ARB), anti-coagulants/anti-
platelets, beta-blockers (BB), digoxin, diuretics, and nitrate. HF-
related healthcare costs and resource utilization were calcu-
lated as per-patient per-year (PPPY) and per-patient per-event. 
Total healthcare costs comprised those covered by the National 
Health Insurance (NHI) fund and direct patient out-of-pocket 
(OOP) costs (both insured and non-insured). 
We examined economic impacts in a variety of clinically rele-
vant patient subgroups and conducted a subgroup analysis of 
costs by patient group focusing on patients who had at least 
one measure for the variables. The study was conducted accord-
ing to the Declaration of Helsinki and approved by the Institu-
tional Review Boards of the six participating hospitals and Sung-
kyunkwan University. 
   
Statistical analysis
We analyzed mean HF-related costs and utilization for 1 year 
per patient and compared them between groups A (hospitalized 
patients) and B (non-hospitalized patients) through mean dif-
ferences. A generalized linear model with gamma distribution 
and log link function were used to evaluate the association be-
tween annual HF-related costs and risk factors. The model con-
trolled for the effects of confounding variables, including age, 
sex, medical comorbidities, medication, and measures of base-
line clinical characteristics by adjustment. The adjusted cost 
ratios (CRs) were reported for each regression. 
p values <0.05 were considered statistically significant, and 
all analyses were conducted using SAS/STAT® version 9.4 (SAS 
Institute Inc., Cary, NC, USA). All costs were estimated in Kore-
an won (KRW; US $1=1,170 KRW in 2016). 
       
RESULTS
Baseline characteristics
A total of 500 patients (mean age, 66.1 years) that consisted of 
228 (45.6%) female and 272 (54.4%) male were included in the 
study (Table 1). Of them, 111 (22.2%) were admitted to the hos-
pital at least once in the post-index period (group A), 389 
(77.8%) had only outpatient visits without any hospitalization 
(group B), 73 (14.6%) were new-onset (de novo) patients, and 
four (0.8%) patients died in the follow-up period.
Among the 500 patients, almost two of every three HF pa-
tients had hypertension (66.4%), followed by atrial fibrillation 
(31.6%) and angina pectoris (17.4%). Moreover, dyslipidemia 
(32.0%) was the most frequent non-cardiovascular comorbid 
condition, followed by diabetes mellitus (DM; 31.4%) and 
chronic kidney disease (CKD; 13.0%). A lower left ventricular 
ejection fraction (LVEF; ≤35%) was significantly more preva-
lent in group A. 
Healthcare resource utilization and costs
Hospitalized patients (group A) had an average of 0.5 emergency 
admissions and 0.9 elective admissions (Table 2). Among the 
hospitalizations, the mean length of stay (LOS) was 7.9 days and 
admissions via the ED had a longer average LOS, compared to 
elective admissions (9.7 days vs. 6.6 days). The mean number 
of annual hospital admissions was estimated at 1.4 for group A, 
and the rates of 30-day and 3-month re-admission were 6.3% 
and 14.4%, respectively. All patients in our sample had at least 
one outpatient visit during the post-index period. The mean num-
ber of visits to the outpatient clinic among all patients was 5.4 (6.9 
in group A vs. 5.0 visits in group B; p=0.111). Patients in group 
A also had higher rates outpatient prescription drug use than 
patients in group B during the 12-month study period. Almost 
75% of patients used anti-coagulants/anti-platelets, followed 
by BBs (71%), diuretics (70.0%), and ARBs (63.4%), while ACEIs 
were prescribed to only 24.6% of patients.
Healthcare costs per patient per year with and without hos-
pitalization during the post-index period were compared. The 
mean PPPY (standard deviation ) for all HF-related healthcare 
costs was KRW 2,607,173 (KRW 6,924,815) for all patients, and 
group A had significantly higher total annual direct healthcare 
costs than group B (KRW 8,530,290 vs. KRW 917,029, respec-
tively; p< 0.001). For patients in group A, the mean annual hos-
pitalization cost per patient was KRW 7,451,844 (KRW 12,349,874), 
and emergency admission comprised 55.1% of the total costs. 
The mean total estimated expenditure per hospital admis-
sion for HF was KRW 5,433,654 (KRW 8,233,311). The cost of 
hospital admissions via the ED (KRW 7,826,223) was 1.9 times 
higher than the cost of elective admissions (KRW 4,118,546). 
When we analyzed costs domains for health care services for 1 
year, the biggest component was costs for tests. The annual mean 
costs for tests were KRW 1,693,772 (21.1%) for group A and 
KRW 124,669 (38.0%) for group B. Costs for medical devices 
comprised 13.7% of all cost for group A and 0.1% for group B, 
respectively (Supplementary Table 1, only online). 
Healthcare costs by patient subgroup 
Fig. 2 shows the mean annual HF-related cost per patient by 
patient subgroup. In patients who experienced hospital admis-
sion via the ED (n=52), the mean 1-year healthcare costs were 
KRW 11,040,453 in total, consisting of 38.7% NHI coverage 
costs (KRW 4,274,415) and 61.3% OOP costs (insured, KRW 
4,176,196; non-insured, KRW 2,589,842). A total of 61 patients 
(55.0%) in group A experienced hospitalization at the index 
date with a mean total cost of KRW 9,088,886. Among the 500 
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patients, 332 were eligible for the subgroup analysis of LVEF. 
Patients with an LVEF ≤35% (n=109) had a significantly higher 
healthcare costs than patients with an LVEF >35% (n=223). 
The total cost for patients with LVEF ≤35% was more than 2.5 
times that of patients with an LVEF >35% (KRW 5,922,184 vs. 
KRW 2,386,219; p=0.006). When the results were classified by 
eGFR, 38 patients had a eGFR <30 L/min/1.73 m2 and 405 pa-
tients had a eGFR ≥30 L/min/1.73 m2. The mean annual HF-re-
lated costs increased by approximately 107% in patients with an 
eGFR <30 L/min/1.73 m2, compared to the cost in those with 
an eGFR ≥30 L/min/1.73 m2. By ICD-10 codes, the total cost of 
patients with ICD-10 I50.x codes was KRW 2,906,364 and KRW 
1,699,948 for patients with I11 or I13 overall. Compared to the 
costs of patients with a previous history of HF, de novo HF pa-
tients had increased costs after the index date (KRW 4,979,932 
vs. KRW 2,438,316; p=0.003). Older age, CKD, and DM were 
also associated with higher HF-related costs. 
Association between risk factors and healthcare costs 
A generalized linear model was used to identify risk factors 
associated with higher mean annual HF-related costs per pa-
tient adjusted for age, gender, previous HF history, and HF-re-
lated medical comorbidities, and medications (Table 3). De 
novo HF was significantly associated with higher total costs 
Table 1. Demographic Characteristics and Medical Comorbidities of the Study Population
Variables
Hospitalized patients 
(group A, n=111)
Non-hospitalized patients 
(group B, n=389)
Total (n=500) p value
Age (yr), mean (SD)   68.0 (14.0)   65.5 (13.1)   66.1 (13.4) <0.001
Age, n (%) 0.053
18 to <65      36 (32.4)    173 (44.5)    209 (41.8)
≥65      75 (67.6)    216 (55.5)    291 (58.2)
Gender, n (%) 0.111
Male      53 (47.7)    219 (56.3)    272 (54.4)
Female      58 (52.3)    170 (43.7)    228 (45.6)
BMI (kg/m2), mean (SD)* 24.5 (4.8) 24.5 (3.6) 24.5 (4.0) 0.944
LVEF ≤35%, n (%)*      49 (45.0)      57 (25.6)    106 (31.9) <0.001
eGFR <30 L/min/1.73 m2, n (%)*        14 (12.96)      24 (7.16)      38 (8.58) 0.061
NYHA, n (%)* <0.001
I      1 (1.7)      36 (31.3)      37 (21.1)
II      47 (78.3)      79 (68.7)    126 (72.0)
III      0 (0.0)      0 (0.0)      0 (0.0)
IV      12 (20.0)      0 (0.0)    12 (6.9)
Previous HF history, n (%) <0.001
No      69 (62.2)    358 (92.0)    427 (85.4)
Yes      42 (37.8)    31 (8.0)      73 (14.6)
Medical comorbidities, n (%)
Hypertension      64 (57.7)    268 (68.9)    332 (66.4) 0.027
Dyslipidemia      13 (11.7)    147 (37.8)    160 (32.0) <0.001
DM      36 (32.4)    121 (31.1)    157 (31.4) 0.791
COPD      9 (8.1)    17 (4.4)    26 (5.2) 0.118
Angina pectoris      16 (14.4)      71 (18.3)      87 (17.4) 0.347
Peripheral vascular disease      6 (5.4)      9 (2.3)    15 (3.0) 0.092
Cerebrovascular disease    11 (9.9)      63 (16.2)      74 (14.8) 0.100
Thyroid disease      2 (1.8)    22 (5.7)    24 (4.8) 0.094
Atrial fibrillation      41 (36.9)    117 (30.1)    158 (31.6) 0.170
Depression      0 (0.0)      5 (1.3)      5 (1.0) 0.230
Malignant tumor      3 (2.7)    14 (3.6)    17 (3.4) 0.646
Myocardial infarction    10 (9.0)      58 (14.9)      68 (13.6) 0.110
CKD      15 (13.5)     50 (12.9)      65 (13.0) 0.855
Valvular heart disease      16 (14.4)       61 (15.7)      77 (15.4) 0.744
BMI, body mass index; LVEF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate; COPD, chronic obstructive pulmonary disease; DM, dia-
betes mellitus; CKD, chronic kidney disease; NYHA, New York Heart Association; HF, heart failure. 
*Subgroup analysis: a total of 391, 332, 443, and 175 patients were included in the BMI, LVEF, eGFR, and NYHA subgroup analysis, respectively, if one or more 
measured value existed during the study period.  
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(CR, 2.4; p<0.001), and HF-related medical comorbidities, 
such as CKD and DM, were linked with increased total costs 
(p=0.007 and 0.004). With regard to medications, the prescrip-
tion of renin-angiotensin system (RAS) inhibitors was associ-
ated with lower average annual costs (CR, 0.6; p=0.007). Age 
and gender were not statistically significant risk factors of HF-
related costs after controlling baseline risk factors. We also 
found that the CR of lower LVEF (≤35%) and eGFR (<30 L/
min/1.73 m2) were still significantly higher than those of the 
reference group (CR, 2.8 and 2.9, respectively; p<0.001).
Sensitivity analysis of healthcare expenditures
As stated above, according to claims database analyses using 
the HIRA National Patient Sample, 15–30% of all patients would 
likely be hospitalized during the post-index period. Accord-
ingly, we analyzed proportions of 15–30% of all hospitalized 
patients (group A) and found that 22.2% had at least one hos-
pitalization during the post-index period. For HF patients, hos-
pitalization costs accounted for the majority of total costs, and 
the mean 1-year HF-related cost per patient increased as the 
proportion of group A increased. Therefore, we performed a 
sensitivity analysis to better reflect the real-world impact (Fig. 3) 
in proportion to group A. For 25% and 30% of patients who ex-
perienced hospitalization among all patients, the mean total 
costs per year were estimated at KRW 2,820,344 and KRW 
3,201,007, respectively. 
Table 2. Medical Resource Use and Costs at 1 Year 
Variables
Hospitalized patients 
(group A, n=111)
Non-hospitalized patients 
(group B, n=389)
Total (n=500) p value
Healthcare utilization, PPPY
Hospitalization
Total, mean (SD) 1.4 (0.8) - 0.31 (0.7) -
Emergency admissions 0.5 (0.7) -   0.1 (0.4) -
Elective admissions 0.9 (0.9) -   0.2 (0.6) -
Inpatient days   7.9 (10.7) - - -
Outpatient utilization
Outpatient visits, mean (SD) 6.9 (3.2) 5.0 (2.2)   5.4 (2.6) 0.111
Prescription drugs (%)
ACEI 31.5 22.6 24.6 0.055
ARB 64.8 62.9 63.4 0.716
Anti-coagulant/anti-platelet 76.5 74.0 74.6 0.588
Beta-blocker 76.5 69.4 71.0 0.142
Digoxin 31.5 23.1 25.0 0.072
Diuretics 87.3 65.0 70.0 <0.001
Nitrate 21.6 13.6 15.4 0.040
Statin 47.7 55.5 53.8 0.147
Healthcare cost, PPPY (KRW 1,000)
Hospitalization 
Total, mean (SD)   7,452 (12,350) -   1,654 (1,779) -
Emergency admissions   4,105 (11,136) -     911 (5,500) -
Elective admissions 3,347 (6,235) -     743 (3,242) -
Outpatient 
Total, mean (SD) 1,078 (1,087) 917 (942)   953 (978) 0.125
Total direct healthcare costs 
Total, mean (SD)   8,530 (12,996) 917 (942)   2,607 (6,925) <0.001
Healthcare cost, PPPE (KRW 1,000)
Hospitalization 
Total, mean (SD) 5,434 (8,233) - - -
Emergency admissions   7,826 (14,756) - - -
Elective admissions 4,119 (6,057) - - -
Outpatient 
Total, mean (SD) 159 (90) 194 (125)   186 (119) 0.002
ARB, angiotensin II receptor blocker; ACEI, angiotensin-converting enzyme inhibitor; PPPY, per-patient per-year; PPPE, per-patient per-event.
US $1=1,170 Korean won (2016). 
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DISCUSSION
To our knowledge, the present study is the first to assess health-
care costs and resource utilization among South Korean pa-
tients with AHF and stable CHF in a real-world population. We 
found that hospitalization contributes 63.4% of the total health-
care costs and that the mean annual total cost of hospitalized 
patients was 9.3 times higher than that of non-hospitalized pa-
tients (p<0.001).
To date, only HF-related costs in South Korea from the Kore-
an Acute Heart Failure (KorAHF) Registry have been published.9 
This registry has focused on hospitalized AHF patients in 10 
tertiary university hospitals with an estimated mean cost per 
admission of 7.7 million won and mean estimated LOS of 8 days. 
In the present study, the estimated average cost of admission 
was 5.4 million won (7.8 and 4.1 million won for ED and elec-
tive admissions, respectively). In relation to HF severity, Lee, et al.9 
reported that more than 80% of patients had severe dyspnea of 
New York Heart Association (NYHA) class III and IV (41% re-
spectively) in the KorAHF registry, whereas nearly 78% had 
NYHA class II and only 4 patients had NYHA class IV in our 
study. HF patients in KorAHF were considered to be more se-
vere than patients in our study. This higher average admission 
cost per the KorAHF, compared to that observed in our study, 
may be attributable to differences in HF patient severity or co-
morbidities and the number of admissions via the ED. 
HF patients often require hospitalization for acute clinical 
deterioration, despite their chronic condition, since their status 
is usually life-threatening and requires urgent treatment in the 
ED.10 The rate of emergency admissions (35.7%) among all hos-
pitalizations observed in the present study was considerably 
lower than the rate of 72% previously reported by the KorAHF 
registry. Related to the proportion of ED visits per year among 
total HF patients, there was a lower proportion in our study 
population, compared with the American Heart Association 
statistics (10.4% vs. 20%). Therefore, it is likely to lead to an un-
derestimation of the average costs in our study, because ED 
visits are associated with increased healthcare costs. Further-
more, among hospitalized patients, only 55% were followed for 
up to 1 year from their index hospitalization, estimating an an-
nual mean cost of KRW 9,088,886, which is 7% higher than 
those of total hospitalized patients. 
The mean annual costs for a patient with HF are estimated to 
be approximately KRW 2,607,173, with hospitalization, outpa-
tient visits, and medication comprising 63.4, 14.8, and 21.7% of 
the costs, respectively. According to HF research costs, expen-
ditures for hospital admissions account for approximately 47–
69% of the total direct costs, consistent with the 63% noted in 
Admitted via ED (n=52) 11,040,453
Age ≥65 (n=252) 3,065,998
eGFR <30 L/min/1.73 m2 (n=38) 5,402,846
Male (n=251) 2,810,799
Hospitalized patients (n=111) 8,530,290
ICD-10 I50 (n=376) 2,906,364
Diabetes (n=146) 3,694,494
AF (n=145) 2,566,383
ICD-10 non-I50 (n=124) 1,699,948
Index hospitalization (n=61) 9,088,886
BMI ≥25 kg/m2 (n=159)
NHI coverage
OOP for non-insured services
Mean cost for all patients
Mean cost for 1 year (KRW)
0 4,000,000 8,000,0002,000,000 6,000,000 10,000,000 12,000,000
OOP for insured services2,779,007
Pa
tie
nt
 g
ro
up
New-onset (n=71) 4,979,932
All (n=500) 2,607,173
TE (n=373) 2,438,316
LVEF ≤35% (n=106) 5,922,184
Female (n=193) 2,888,893
CKD (n=58) 3,674,446
COPD (n=24) 2,462,524
Non-hospitalized (n=389) 917,029
Fig. 2. Subgroup analysis of healthcare expenditures per patient per year. US $1=1,170 Korean won (2016). BMI, body mass index; LVEF, left ventricular 
ejection fraction; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; TE, treat-
ment experienced; ED, emergency department; NHI, National Health Insurance; OOP, out-of-pocket; ICD-10, International Classification of Disease, 
10th edition; AF, atrial fibrillation.
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this study. Similarly, drug costs have been found to account for 
16% of the total direct costs of HF in Ireland, 18% in the UK, and 
18% in Sweden, findings that are consistent with the 21.7% in of 
our study.11
Based on HF management guidelines, ACEI, ARB, BB, digoxin, 
and diuretics are the most commonly prescribed drugs, and the 
use of first-line ACEI is recommended.12,13 Patients in European 
and North America use ACEI 3 to 5 times more commonly than 
ARB, while Choi, et al.14 reported that ARB use was higher than 
ACEI use at discharge in the Korean registry (39.4% vs. 17.9%, 
respectively). In the present study, the rate of ACEI use over 1 
year (24.6%) was considerably lower than that of ARB (63.4%). 
Table 3. Association Between Risk Factors and HF-Related Costs 
Risk factors n
Adjusted 
coefficients
95% confidence interval
p value
Adjusted
cost ratioLower Upper
Age (yr) 500  -0.004 -0.011 0.004 0.308 1.0
Gender 500
Female Reference
Male  -0.091 -0.300 0.117 0.391 0.9
HF history 500
ADHF Reference
New-onset   0.877 0.601 1.152 <0.001 2.4
Hypertension 500
No Reference
Yes  -0.296 -0.505 -0.088 0.005 0.7
DM 500
No Reference
Yes   0.338 0.111 0.565 0.004 1.4
COPD 500
No Reference
Yes   0.022 -0.403 0.447 0.920 1.0
CKD 500
No Reference
Yes   0.401 0.111 0.691 0.007 1.5
Medication 500
None Reference
RASI and BB  -0.327 -0.728 0.075 0.111 0.7
RASI only  -0.579 -1.003 -0.156 0.007 0.6
BB only   0.083 -0.411 0.577 0.741 1.1
BMI  391*
BMI <25 kg/m2 Reference
BMI ≥25 kg/m2  -0.125 -0.366 0.117 0.311 0.9
LVEF  332*
LVEF >35% Reference
LVEF ≤35% 1.01 0.766 1.258 <0.001 2.8
eGFR  443*
eGFR ≥30 L/min/1.73 m2 Reference
eGFR <30 L/min/1.73 m2   1.045 0.560 1.535 <0.001 2.9
NYHA 175*
I Reference
II   0.748 0.429 1.068 <0.001 2.1
III NA NA NA NA
IV   1.596 1.013 2.179 <0.001 4.9
ADHF, acute decompensated heart failure; BMI, body mass index; LVEF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate; COPD, chron-
ic obstructive pulmonary disease; DM, diabetes mellitus; CKD, chronic kidney disease; RASI, renin-angiotensin system inhibitor; BB, beta-blocker; NYHA, New 
York Heart Association; HF, heart failure.
*A total of 391, 332, 443, and 175 patients were included in the BMI, LVEF, eGFR, and NYHA subgroup analysis, respectively, if one or more measured value ex-
isted during the study period.   
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There was a certain discrepancy between western countries 
and Korea in the drug use pattern of ACEI/ARB. ACEIs have a 
proven survival benefit for HF patients; however, the higher 
rate of dry cough in South Korean patients has led to greater 
utilization of ARBs.
Several risk factors for higher costs were identified. First, we 
found that moderate to severe renal dysfunction, such as an 
eGFR <30 L/min/1.73 m2, increased total HF-related health-
care expenditures. Renal dysfunction is common in patients 
with HF.15 McAlister, et al.16 and Cleland, et al.17 reported that 
renal insufficiency is associated with poorer outcomes in pa-
tients with HF. An eGFR <30 L/min/1.73 m2 at baseline was 
significantly associated with increased total costs (CR, 2.9; 
p<0.001) and a 1-year per capita healthcare cost approximately 
2 times higher than an eGFR >30 L/min/1.73 m2. Moreover, our 
results demonstrated that the presence of CKD in patients with 
HF also contributes to high costs (CR, 1.5; p=0.007). Since the 
average age of our population was 66.1 years and age is a ma-
jor risk factor for CKD, careful monitoring for CKD is recom-
mended for patients with HF.18 Second, 57.6% of de novo HF 
patients in our population experienced at least one hospital-
ization, compared to 16.6% of prevalent patients, which led to 
greater personal spending and more frequent use of health-
care resources. Smith, et al.19 suggested that the difference in 
cost pattern between de novo and acute decompensated HF 
(ADHF) patients would likely result from differences in clini-
cal profiles. Metra, et al.20 reported that patients with de novo 
AHF are more likely to experience cardiology shock, have pul-
monary edema, be hypertensive on admission, or have acute 
coronary syndrome. Patients with ADHF more frequently 
present with a history of myocardial infarction and medical co-
morbidities, such as DM, CKD, and chronic obstructive pul-
monary disease. Once an acute cardiac event results in patho-
logical remodeling, a patient enters a repeated clinically stable 
and unstable situation. The results of this process are increased 
healthcare spending in patients with HF, particularly re-hospi-
talization.21 Therefore, American Heart Association/American 
College of Cardiology guidelines emphasize intensive treatment 
for the early phase of HF. Third, increased healthcare costs were 
associated with low LVEF in patients with HF. According to the 
Korean CHF guideline, the survival rates of patients with HF 
reduced ejection fraction (HFrEF) are likely to be lower or simi-
lar to that of patients with HF preserved ejection fraction.22 Sev-
eral studies showed no difference in mortality rates between 
patients with systolic HF and those with diastolic HF, although 
they included relatively small sample sizes. Meanwhile, the 
Cardiovascular Health study found that patients with HFrEF 
had lower survival rates than patients with a normal EF.23,24 
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Fig. 3. Sensitivity analysis of healthcare expenditures per patient per year. US $1=1,170 Korean won (2016). HF, heart failure.
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Fourth, findings from our study suggest that the administration 
of RAS inhibitors may provide the additional benefit of low-
ered healthcare costs in patients with HF, whereas the admin-
istration of BB may not. Our multivariate analysis results are 
consistent with those of some recent reports. In a retrospective 
analysis of patients with HF or myocardial infarction discharged 
from the hospital, adherence and persistence of RAS inhibitors 
had a significant negative effect on total healthcare costs.25 Obi, 
et al.26 suggested that therapy with BB alone was associated 
with a higher risk of cost increases than RAS inhibitor mono-
therapy at 1–6 months before death in multivariate analyses. We 
ultimately observed higher costs and HF re-hospitalization 
rates during the post-index period in patients with I50.x diag-
nostic codes, compared to patients with I11 and I13 diagnos-
tic codes. Several administration studies used only I50 codes to 
define HF, while some studies defined HF using I50, as well as 
I11, I13, and I42 as extended HF codes. We defined HF using 
I50, I11.0, I13.0, and I13.2 because cardiomyopathy (I42) is the 
main disease in many cases of HF. The mean total cost in pa-
tients with a diagnostic code of I50.x was higher than the mean 
total costs of other patients. In general, patients with pure HF 
codes (I50.x) have relatively severe symptoms and signs, com-
pared to patients with hypertensive heart disease and HF. In 
our analysis, patients with hypertension had lower costs than 
those who did not. We included approximately 25% of patients 
with extended HF codes, which may have underestimated the 
overall burden of HF. 
Several limitations should be considered when interpreting 
our study’s results. There are inherent limitations associated 
with any retrospective data collection based on medical chart 
review. The association between total healthcare costs and risk 
factors is subject to bias, because some potential confounding 
factors that were not collected in our study might have affected 
the results of these analyses, and selection bias can occur in 
retrospective cohort studies. The study population was collect-
ed from tertiary referral hospitals and one general hospital, all 
of which are affiliated with universities and had a cardiovas-
cular center comprised of specialists for HF. Also, the 500 sam-
ples may likely have had more severe disease than that for the 
entire population, since we focused on patient identified by ex-
act HF diagnosis. For this reason, we used few exclusion crite-
ria to maximize the external validity of generalization to all 
patient populations. Stratifying patients based on hospitaliza-
tion experience and subgroup analyses allowed more flexibil-
ity in the interpretation of the results, but it remains possible 
that total healthcare costs per patient per year may have been 
underestimated due to the low proportion of hospitalized pa-
tients and those who died in the post-index period.   
To our knowledge, this study is the first to assess healthcare 
costs for patients with acute hospitalized and CHF in South 
Korea. Our research builds on a larger body of empirical re-
search concerning HF-related costs and will lead to additional 
studies that provide stronger evidence. We found that the ma-
jority of healthcare costs were related to hospitalization, espe-
cially those via ED admissions. Appropriate treatment strate-
gies to prevent or decrease hospitalization are needed to reduce 
the economic burden on HF patients, and comorbid conditions 
and risk factors may be important targets for disease manage-
ment efforts.  
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